Marvin & Palmer Associates Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ConocoPhillips
COP
|
+$10.7M |
| 2 |
UnitedHealth
UNH
|
+$10.1M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
+$10.1M |
| 4 |
Cencora
COR
|
+$9.97M |
| 5 |
VanEck Agribusiness ETF
MOO
|
+$9.74M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$12.6M |
| 2 |
Blackstone
BX
|
+$12.1M |
| 3 |
Edwards Lifesciences
EW
|
+$11.9M |
| 4 |
Goldman Sachs
GS
|
+$11.2M |
| 5 |
Applied Materials
AMAT
|
+$10.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 21.81% |
| 2 | Healthcare | 14.74% |
| 3 | Technology | 14.25% |
| 4 | Energy | 13.25% |
| 5 | Consumer Discretionary | 9.06% |
Similar funds
Marvin & Palmer Associates's Q1 2022 Portfolio in Review
As of Q1 2022, Marvin & Palmer Associates held 41 positions worth $222M, down 5% from $234M the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Marvin & Palmer Associates withdrew a net $15.7M in Q1 2022, closing 12 positions and reducing 12 holdings. Its most notable exit was Lam Research, an estimated $12.6M position sold in full.
By sector, the portfolio is most concentrated in Financials at 22% of assets, down from 24% a quarter earlier, followed by Healthcare and Technology.
Against the trend, Marvin & Palmer Associates opened a new position in ConocoPhillips worth $11.7M.
- Marvin & Palmer Associates's largest Q1 2022 buy was ConocoPhillips: 116,767 shares worth $11.7M.
- Marvin & Palmer Associates added most to Palo Alto Networks in Q1 2022, an estimated $1.42M increase.
- Marvin & Palmer Associates's biggest Q1 2022 reduction was Applied Materials, cutting an estimated $10.8M.
- Marvin & Palmer Associates fully exited Lam Research in Q1 2022, selling an estimated $12.6M.
- Marvin & Palmer Associates's ten largest holdings make up 49% of its $222M portfolio in Q1 2022.
- Marvin & Palmer Associates opened 16 new positions and closed 12 in Q1 2022.
- Marvin & Palmer Associates's portfolio value fell 5% quarter-over-quarter to $222M.
Based on Marvin & Palmer Associates's 13F filing for Q1 2022, filed 11 May 2022.